Dataset Information

Bowel cancer screening participation rate in a program that offers blood tests as well as faecal tests as screening options.

ABSTRACT: Interventions: The intervention is a bowel cancer screening program that includes the availability of a screening blood test after an offer of the standard faecal occult blood test (FOBT). There are two intervention groups (n = 600 per group). Everyone in the intervention will be initially mailed an offer of screening for bowel cancer by FOBT. For the first intervention group, after 12 weeks anyone who has not participated with the FOBT will be mailed an offer of screening for bowel cancer by blood test (the methylated BCAT1/IKZF1 blood test). They will then need to call the study helpline to request a further blood test information. The second intervention group will be sent the offer for the blood test at the same time as receiving the FOBT. They will be advised that if they believe that the FOBT is not suitable for them they might consider screening for bowel cancer by blood test. They will then need to call the study helpline to request a further blood test information. Anyone requesting the blood test will then be sent information about the test (including accuracy of the test, where they can get their blood collected, and when they will receive their test results) and a test referral. They can then take up the offer of the free screening blood test at one of 10 local blood collection centres (Healthscope). They do not need to be fasted and appointments do not need to be made. Reminder letters will be sent to non-participants 6 weeks after each type of screening test offer. Participants of the FOBT will be required to collect a small sample from two separate bowel movements. These samples are then sent via reply-paid mail to a laboratory which tests the samples for the presence of blood. If more than 100ng/mL of blood is present in either sample, Primary outcome(s): Total participation rate in a bowel cancer screening program that offers a FOBT followed by a blood test, compared to a program that only offers FOBT. This will be assessed at the 24 week timepoint by review of laboratory records.[24 weeks after the initial screening offer.] Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Efficacy

DISEASE(S): Public Health-health Service Research,Colorectal Cancer,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)

PROVIDER: 2462649 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:Interventions: Eligible people (n = 240) within the SCOOP program (a colonoscopy surveillance program for individuals at higher risk for bowel cancer) at Repatriation General Hospital or Flinders Medical Centre who do not screen for bowel cancer via the standard means (ie. faecal testing), will be sent a letter to invite them to screen for bowel cancer with a blood test (Colovantage Plasma), as well as a short survey to ascertain their demographic details and their screening history. Anyone interested in taking up the blood screening test will be asked to fill in the consent form and request form and send them back (in the provided reply paid envelope) to the Bowel Health Service. Following receipt of the blood test request form, the study enrolee will then be sent further information on the blood test (including information on the accuracy of the test, where they can get their blood collected, and when they will receive their test results) and a test referral. They can then take up the offer of the free screening blood test at one of four local blood collection centres (Healthscope). They do not need to be fasted and appointments do not need to be made. Reminder letters will be sent after 6 weeks to those people who have not taken up the blood test screening offer. Screening participation rate with the blood test and demographic factors that influence uptake, will be assessed at the 12 week time point. Primary outcome(s): The primary outcome is to determine how many people within 12 weeks following the invitation letter have a blood sample collected for bowel cancer screening (ie. outcome = blood test participation rate). The number that complete the blood test will be expressed as a percentage of the invited cohort (ie. 240)[12 weeks after invitation to screen.];An additional primary outcome will be to determine the factors that predict screening uptake with the blood test, ie. age, gender, risk status for bowel cancer, reasons for not participating with faecal testing. This information will be established via a short survey (designed specifically for this study) that is provided with the original study invitation letter.[12 weeks after invitation to screen.] Study Design: Purpose: Prevention; Allocation: Non-randomised trial

Project description:Interventions: Name of intervention: gender specific mail-administered screening invitation strategies. All participants will receive an offer to participate in a free FOBT which will be delivered by mail. Intervention arms will differ from control according to the information included in the materials accompanying the screening offer. All study participants will receive a standard screening reminder irrespective of their intervention group. Intervention materials will target specific psychosocial variables previously identified as being related to male participation in FOBT screening. The intervention period is 14 weeks. All participants will receive a screening offer according to the following timeline. Baseline: Advance notification letter sent Week two: Invitation package sent Week eight: Reminder letters sent to those who have not completed an FOBT Week 14: Data collection ceases. Arm 1: Control The control arm will receive a standard offer to participate in FOBT screening designed to mimic the strategy utilised by the Australian national bowel cancer screening program (NBCSP). The standard offer includes an advance notification letter and a screening invitation package. The advance notification letter is sent two weeks prior to the screening invitation package and is designed to alert participants that an invitation to screen for CRC with an FOBT will soon follow. The standard advance notification letter introduces basic information about colorectal cancer and the health benefits of screening. The screening invitation package includes a) a screening invitation letter b) an immunochemical FOBT with associated instructions c) an information booklet that describes colorectal cancer and screening and d) a particip Primary outcome(s): Rate of FOBT participation per trial arm as assessed by number of FOBT screening tests returned.[At 14 weeks from baseline, 12 weeks after receiving the FOBT.] Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Factorial;Type of endpoint: Efficacy

Project description:Interventions: The intervention is a SMS personalised message from the general practice sent to the patient’s smartphone with links to: 1. A message from the general practitioners (GPs) at the general practice (e.g. Hello. xxx This is a health message from the GPs at xxx Medical Practice. Your free bowel cancer screening kit will arrive in the post soon. We strongly encourage you to do this test. If cancer is detected early over 90% of bowel cancers are successfully treated. We recommend that you watch the videos below.) 2. A video of a person talking about their positive experience of doing the National Bowel Cancer Screening Program (NBCSP) Immunochemical Faecal Occult Blood Test (IFOBT) test 3. A animated video demonstrating how to complete the test 4. Links to information from Cancer Council Australia The SMS is sent from the general practice one month prior to patients 50th, 52nd, 54th, 56th, 58th and 60th birthdays. The intervention period is six months long, there will be 6 rounds of SMS sent during that time to any active patient due to receive their NBCSP kit. Patients will only receive one SMS. The number of patients due to be sent the SMS will be recorded in PEN CAT4 clinical audit software and the number of SMS sent is recorded on the GoShare Plus platform. Data, the number of patients due to receive the SMS and the number of SMS sent is recorded at the general practice. This data is collected by the project manager. Primary outcome(s): The primary outcome will be the proportion of patients who complete the NBCSP after six months from the total number of eligible patients who are about to have their 50th, 52nd, 54th, 56th, 58th, or 60th birthdays. This outcome will be measured by the number of FOBT results sent to the general practice for patients in this age group. Aggregate data (number of FOBTs returned in each age group) will be collected from the electronic medical records. [From commencement of the 6 month intervention period to 6 months after completion of the intervention period. ] Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy

Project description:Interventions: There are two intervention arms: Intervention arm 1 is an ‘SMS-only’ sent from general practice to patients, Intervention arm 2 is an ‘SMS-bundle’ - an SMS with additional video material sent from general practice to patients. The study is a cluster randomised controlled trial with the cluster unit being individual general practices. The intervention will be sent from general practices using an SMS service ‘GoShare’ depending on the cluster that the general practice has been randomised into. The SMS-only/SMS-bundle will be sent to eligible patients two weeks prior to when their National Bowel Cancer Screening Program (NBCSP) kit is due to arrive. The participants will only be sent one SMS-only or SMS-bundle. 1. The SMS-only is sent from a patient s general practice is to prompt patients to do the NBCSP kit. The SMS contains a greeting and the patient s first name, general practice name and telephone number, a GP endorsement of the NBCSP and the option to ‘opt-out’ of receiving future SMS. The wording in the SMS is: ‘Hi [insert patient first name]. Your free bowel cancer screening kit will arrive in the post soon. [insert general practice name] strongly encourages you to do this test. Call us on [insert general practice telephone number] if you have any questions. Reply STOP to opt out’. 2. The SMS-bundle is the SMS as described above, but with an web link to a GP message with the general practice logo and endorsing the NBCSP, a video of relatable people talking about why it is important to do the kit (approx 30 seconds long), an instructional video on how to do the kit (approx 45 seconds long), and a link to more information about the NBCSP. The wording is: ‘Hi [insert patient first name]. Your free bowel cancer screening kit will arrive in the Primary outcome: The primary outcome will be the difference in the proportion of patients who have a faecal occult blood test (FOBT) result recorded by the National Cancer Screening Register between the control arms and both interventions. This will be analysed by sex, age and location.[ The time point will be 6 months after the intervention phase is completed (SMS has been sent to patients). ] Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy

Dataset Information

Bowel cancer screening participation rate in a program that offers blood tests as well as faecal tests as screening options.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets